Company intelligence / Profile preview

Yirida Group

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Yirui Pharma has established a comprehensive R&D platform specializing in small molecule drugs for autoimmune, inflammatory, and metabolic diseases, using structure-based medicine and screening technologies; clinical results are not yet public.

Therapeutic areas: OphthalmologyDermatologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Partnerships

Academic institutions in China and abroadpharmaceutical company technology in-licensing and co-development partnerships (details not disclosed)

Beyond the preview

Go deeper on Yirida Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yirida Group.

Explore the full profile